| | | | | Epidemiology and natural history of AAA
|
| | | | Hans-Henning Eckstein, Rebecka Hultgren
|
| 08.30 | | | When is the prevalence too low to motivate continued screening? Sverker Svensjö  |
| 08.38 | | | The New Zealand AAA-specific risk scoring tool, Gregory Jones  |
| 08.46 | | | Aneurysm rupture is not simply a mechanical event: how so and what are the implications? Rao Vallabhaneni  |
| 08.54 | | | Female sex is not an independent risk factor for higher periprocedural mortality rates of AAAs - the nationwide Swedish DRG microdata from 2000-2016 on >50.000 cases, including socioeconomical aspects, Rebecka Hultgren |
| 09.02 | | | Why do women have higher operative mortality than men for aortic aneurysm repair? Janet Powell  |
| 09.10 | | | Do all 25-29 mm ectatic aortas progress to AAAs actually needing repair? Sverker Svensjö  |
| 09.18 | | | Short communication: blood glucose, diabetes and abdominal aortic aneurysm among 2 million screened individuals, Dylan Morris  |
| 09.22 | | | Short communication: should we screen women for abdominal aortic aneuvrysm, Pinar Ulug  |
| 09.26 | | | Short communication: the TAGA study: a new family study for the genetic analysis of aortic abdominal aneurysm, Maria Sabater-Lleal  |
| 09.30 | | | Discussion |
| 09.45 | | | Frank Lederle lectures, Ronald Dalman |
| | | | |
| 10.05 | | | Coffee break |
| | | | Ask to expert II (Nagelmackers room – Level 2) |
| | | | How can we avoid spinal cord ischemia during TEVAR/EVAR for Aortic aneurysms? John Elefteriades |
| | | | Case presentation : paraplesia, a rare complication of EVAR for AAA, Vincent Tchana-Sato |
| | | | |
| | | | | Medical treatment of AAA |
| | | | Ronald Dalman, Anders Wanhainen |
| 10.35 | | | AAA: is there a role for the prevention and therapy using antioxidants? Joël Pincemail  |
| 10.45 | | | Could metformin be a drug effective in limiting AAA growth and requirement for surgery: data from a large group of cohorts, Jonathan Golledge  |
| 10.55 | | | Ticagrelor and the inhibition of growth in small AAAs – results from a RCT, Anders Wanhainen
|
| 11.05 | | | The role of fish oil in the natural history of AAA, Jes Lindholt  |
| 11.15 | | | Hormone replacement therapy and AAA - A HUNT study based on 20.000 women, Rebecka Hultgren |
| 11.25 | | | Role of resveratrol and the bone protein sclerostin in protection from AAA, Jonathan Golledge
|
| 11.35 | | | Cipro and the aorta - Fluoroquinolone attack? Bulat Ziganshin  |
| 11.45 | | | What diabetes can teach us about AAA? Ronald Dalman
|
| 11.55 | | | Short communication: final findings of the fenofibrate in the management of abdnominal aortic aneuvrysm (fame) - 2 trial, Joseph Moxon  |
| 12.00 | | | Discussion |
| | | | |
| 12.30 | | | Lunch break |
| | | | |
| | | | | EVAR & TEVA |
| | | | Colin Bicknell, Kakkhee Yeung |
| 13.53 | | | The role of open surgery for AAA in the endovascular era, Franco Grego  |
| 14.01 | | | The effect of clinical, psychosocial and socio-demographic variables on mental and physical functioning after vascular surgery, Colin Bicknell |
| 14.09 | | | The UK Complex Aneurysm study: an overview, Rao Vallabhaneni  |
| 14.17 | | | Endoleaks in EVAR, risk factors and prevention, Eric Allaire  |
| 14.25 | | | Wide proximal aortic neck in the outcome of EVAR, Athanasios Giannoukas  |
| 14.33 | | | Acute kidney injury after endovascular surgery: results from a pilot randomized controlled trial and a cohort study, Athanasios Saratzis  |
| 14.41 | | | Importance of changes in thoracic and abdominal aortic stiffness following stent graft implantation, Christos Liapis  |
| 14.49 | | | Prevention of stent graft migration after TEVAR: mathematical model, Milos Sladojevic  |
| 14.57 | | | Results of endurant study (follow-up and comparison with Ace study), Jean-Pierre Becquemin  |
| 15.05 | | | What do we know about AD risk factors for later problems? Jan Brunkwall  |
| 15.13 | | | Discussion |
| | | | |
| 15.30 | | | Coffee break |
| | | | Ask to expert III (Nagelmackers room – Level 2) |
| | | | Spinal cooling catheter: new concept in paraplesia prevention, John Elefteriades |
| | | | |
| | | | | Associations in aortic aneurysmal disease |
| | | | Thomas Bilfinger, Nicos Labropoulos |
| 16.05 | | | Arterial aneurysms associated with the aorta, Nicos Labropoulos  |
| 16.13 | | | Is AAA a risk factor for neoplasia? Natzi Sakalihasan |
| 16.21 | | | What is the association between AAA, hernia and simple renal cyst? Apostolos Tassiopoulos  |
| 16.29 | | | Incidence of AAA is higher in the patients with COPD and smoking - why? Thomas Bilfinger  |
| 16.37 | | | Are abdominal aortic aneurysms different in patients with and without concurrent athero-occlusive disease? Jonathan Golledge |
| 16.45 | | | Cardiovascular risk management in patients with small AAA, Matthew Bown |
| 16.53 | | | Discussion |
| | | | |
| | | | | Management of aortic graft infections |
| | | | Hans-Henning Eckstein, Rebecka Hultgren |
| 17.15 | | | Endovascular repair is effective in emergency but definitive excisional graft removal is the aim for all infected aortic grafts and endografts, Colin Bicknell  |
| 17.23 | | | The place of allografts in the management of aortic graft infections, Evelyne Boesmans  |
| 17.31 | | | Treatment of vascular infection with arterial homografts: 27 years of experience at European Homograft Bank (EHB) in Brussels, Ramadan Jashari  |
| 17.39 | | | How to treat an infected aortic endograft by in-situ reconstruction with pericard tube grafts? Hans-Henning Eckstein  |
| 17.47 | | | Discussion |
| | | | |
| 18.15 | | | Awards ceremony and adjournment |
| | | | |